Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Iterum Therapeutics PLC
NASDAQ ITRM
Data sourced from
and
and
Iterum Therapeutics PLC Debt to Capital Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 107.22%
Iterum Therapeutics PLC Debt to Capital Ratio 2 year CAGR is 107.22% for the Trailing 12 Months (TTM) ending March 31, 2024. The debt to capital ratio measures the proportion of a company's total capitalization that is financed by debt. It is calculated by dividing total debt by the sum of total debt and shareholders' equity. This ratio provides insights into the capital structure and financial risk of the company. A higher ratio indicates a greater reliance on debt financing. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Iterum Therapeutics PLC Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.36, a 4.77% change year over year.
-
Iterum Therapeutics PLC Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.35, a 123.61% change year over year.
-
Iterum Therapeutics PLC Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -1.47, a -10.27% change year over year.
-
Iterum Therapeutics PLC Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -1.34, a -795.47% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ITRM
| CEO | Mr. Corey N. Fishman |
| IPO Date | May 25, 2018 |
| Location | Ireland |
| Headquarters | Fitzwilliam Court, Dublin, Ireland, 2 |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Key trends
Similar companies
Hoth Therapeutics Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email